Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;52(2):144-150.
doi: 10.1310/hpj5202-144.

Irinotecan Liposome Injection

Danial E Baker, Terri L Levien

Irinotecan Liposome Injection

Danial E Baker et al. Hosp Pharm. 2017 Feb.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The February 2017 monograph topics are bezlotoxumab, binimetinib, broadalumab, deuterabenazine, prasterone vaginal, and valbenazine. The DUE is on bezlotoxumab.

PubMed Disclaimer

Similar articles

  • Bezlotoxumab.
    Baker DE. Baker DE. Hosp Pharm. 2017 Mar;52(3):229-233. doi: 10.1310/hpj5203-229. Hosp Pharm. 2017. PMID: 28439138 Free PMC article.
  • Insulin Degludec/Liraglutide.
    Baker DE. Baker DE. Hosp Pharm. 2017 May;52(5):374-380. doi: 10.1177/0018578717715383. Epub 2017 May 1. Hosp Pharm. 2017. PMID: 28804155 Free PMC article. Review.
  • Sugammadex.
    Cada DJ, Levien TL, Baker DE. Cada DJ, et al. Hosp Pharm. 2016 Jul;51(7):585-96. doi: 10.1310/hpj5107-585. Hosp Pharm. 2016. PMID: 27559192 Free PMC article.
  • Formulary Drug Review: Ocrelizumab.
    Ali ZK, Baker DE. Ali ZK, et al. Hosp Pharm. 2017 Oct;52(9):599-606. doi: 10.1177/0018578717731733. Epub 2017 Sep 17. Hosp Pharm. 2017. PMID: 29276296 Free PMC article. Review.
  • Eteplirsen.
    Baker DE. Baker DE. Hosp Pharm. 2017 Apr;52(4):302-305. doi: 10.1310/hpj5204-302. Hosp Pharm. 2017. PMID: 28515510 Free PMC article.
See all similar articles

Cited by

References

    1. Onivyde (irinotecan liposome injection) [prescribing information]. Cambridge, MA: Merrimack Pharmaceuticals Inc.; October 2015.
    1. Merrimack Pharmaceuticals. . Study of nanoliposomal irinotecan (Nal-IRI)-containing regimens in patients with previously untreated, metastatic pancreatic adenocarcinoma. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02551991. Updated July 28, 2016. Accessed September 14, 2016. NLM Identifier: NCT02551991.
    1. MM-398. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/results?term=MM-398&Search=Search. Accessed September 14, 2016.
    1. Chibaudel B, Maindrault-Gœbel F, Bachet JB, . et al. PEPCOL: A GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med. 2016; 5( 4): 676– 683. - PMC - PubMed
    1. Roy AC, Park SR, Cunningham D, . et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013; 24( 6): 1567– 1573. - PubMed

LinkOut - more resources